We study antiviral immunity and viral disease pathogenesis. #COVID19 #longCOVID #vaccines @HHMINEWS @YaleIBIO @YaleMed @YaleCII
New Haven, CT
- Tweets 14,776
- Following 1,929
- Followers 211,025
- Likes 53,052
Pinned Tweet
To all aspiring young #WomenInSTEM:
Mentee: Should I avoid being pregnant while trying to secure a faculty position?
Me: Be pregnant & go on interviews. If they don’t welcome you with open arms and offer childcare options, they don’t deserve you. #KnowYourWorth
493
1,379
9,298
Very much looking forward to our annual @YaleCII symposium featuring fantastic speakers 🤩
Please register and submit an abstract. Everyone is invited! (Zoom link will become available closer to the date)
medicine.yale.edu/event/yale…
8
21
87
10,917
👇💯👇
Thank you for everything you do for your patients and for research, @WesElyMD !
Big H/T to @VirusesImmunity and @MichaelPelusoMD
jamanetwork.com/journals/jam…
3
5
1,415
Prof. Akiko Iwasaki retweeted
Exciting opportunity at Yale 📢 We are seeking a Medical Director for the Yale New Haven Hospital Multi-Specialty Long COVID Care Center. Pls spread the word!
Interested candidates should contact @LisaSandersMD.
#LongCOVID #Medicine #InternalMedicine #PostAcuteInfectionSyndrome
9
113
263
22,107
Prof. Akiko Iwasaki retweeted
Why do some patients develop chronic conditions after a #ViralInfection? Scientists interested in post-infection disorders are now joining forces to find out.
“Many collaborations are happening, starting from long-COVID researchers reaching out to people who’ve been doing ME/CFS research for decades,” says Dr. Akiko Iwasaki (@VirusesImmunity) from @YaleMed.
😷 go.nature.com/4xQ9otQ
2
9
27
2,308
Prof. Akiko Iwasaki retweeted
Great opportunity for colleagues in North America/Canada to lead an important clinical/research program at @Yale
Exciting opportunity at Yale 📢 We are seeking a Medical Director for the Yale New Haven Hospital Multi-Specialty Long COVID Care Center. Pls spread the word!
Interested candidates should contact @LisaSandersMD.
#LongCOVID #Medicine #InternalMedicine #PostAcuteInfectionSyndrome
7
14
3,384
Exciting opportunity at Yale 📢 We are seeking a Medical Director for the Yale New Haven Hospital Multi-Specialty Long COVID Care Center. Pls spread the word!
Interested candidates should contact @LisaSandersMD.
#LongCOVID #Medicine #InternalMedicine #PostAcuteInfectionSyndrome
9
113
263
22,107
This physician leader will direct a highly effective multidisciplinary clinic that cares for patients with Long COVID while helping shape the future of post-acute infection syndrome care. (3/)
1
10
30
2,054
We are so grateful to the legendary @LisaSandersmd, the inaugural director of the @YNHH Long COVID Care Center, for making it such a success. We wish her the very best in her retirement later this year. Also grateful to @YNHH and @YaleMed for continuing to support the Center 🙏🏼
7
24
1,311
Prof. Akiko Iwasaki retweeted
Sharing for those here in the Bay: @ChronicleBioAI is looking for ME/CFS patients to enroll in their biobank study who are able to give a blood sample at their Menlo Park lab. They are currently looking at specific biomarkers and immune cells.
connect.chroniclebio.com/sig…
2
22
39
5,922
Prof. Akiko Iwasaki retweeted
#ISLCPAIS2026 abstract review.
My thoughts on abstract 2
One of my fav studies which basically replicates @VirusesImmunity bigger studies in transfer of IgG from
patients with #longcovid to mice.
This study provides further evidence for an immune-mediated mechanism of pain in Long COVID, showing that patient-derived IgG targets peripheral sensory neurons in vivo and ex vivo. These findings strengthen the rationale for testing immunomodulatory approaches such as IVIG in carefully designed clinical trials.
Importantly, funding strategies should not focus exclusively on viral persistence: the growing evidence for pathogenic autoantibodies and immune-mediated neuronal dysfunction makes immunomodulation a parallel, high-priority therapeutic avenue that warrants properly powered clinical trials. I’m surprised this is still not on the priority list
3
11
48
3,558
Prof. Akiko Iwasaki retweeted
＃コロナ後遺症 は一律の治療ではなく、自己抗体やウイルス残存など病気の原因ごとに患者を分類し、それぞれの原因を標的とした治療を行う「プレシジョン・メディシン（精密医療）」への転換が必要です。
@VirusesImmunity
@sam_heds
@k_hirahata
A recent YSM study published in @CellCellPress links #LongCOVID symptoms in some patients to specific autoantibodies, suggesting #autoimmunity as one cause of post-infection illness.
First author @keylas3 and senior author @VirusesImmunity share how their findings could lead to new diagnostic tools and #treatment options.
Learn more: bit.ly/4u00lDJ
1
17
52
5,823
Prof. Akiko Iwasaki retweeted
A recent YSM study published in @CellCellPress links #LongCOVID symptoms in some patients to specific autoantibodies, suggesting #autoimmunity as one cause of post-infection illness.
First author @keylas3 and senior author @VirusesImmunity share how their findings could lead to new diagnostic tools and #treatment options.
Learn more: bit.ly/4u00lDJ
1
24
62
12,898
Prof. Akiko Iwasaki retweeted
"Prime and spike" for tissue-resident memory T cell (TRM) build-up is what we need!
Excellent study and 🧵👇
Thank you @VirusesImmunity 👏
New preprint by @alex_winnett @S_Tabachnikova et al.! We asked: which cellular immune signals control viral replication in the nose during the first days of SARS-CoV-2 infection — and how do they change with vaccination? With @ismagilovlab (1/)
medrxiv.org/content/10.64898…
2
16
60
7,924
Prof. Akiko Iwasaki retweeted
Frühes IFN-γ bedeutet deutlich weniger SARS-CoV-2-Virus - eine vorherige COVID-Impfung war mit früheren IFN-γ-Antwort assoziiert
Nicht die frühe Typ-I-Interferon-Antwort, sondern eine möglichst frühe Typ-II-Interferon-(IFN-γ)-Antwort der Schleimhaut ist mit einer deutlich …
ALT Graphical Abstract. Among participants who prospectively collected daily, paired specimens from multiple upper respiratory anatomical sites while enrolled in a case-ascertained COVID-19 household transmission study conducted in Los Angeles, California between September 2020 and April 2022, a subset of participants were found to initially be negative upon enrollment but later became positive for SARS-CoV-2. These were defined as Cases of naturally acquired, incident SARS-CoV-2 infection, and for whom age, sex, and prior COVID-19 vaccination status matched Control participants without SARS-CoV-2 infection were identified, and demographic data is shown. Samples underwent viral load quantification by RT-qPCR, validated by RT-ddPCR, and human transcriptome sequencing to calculate immune pathway activation and determine the timing of Type I and II IFN response initiation, and expression of a tissue resident memory T cell (TRM) signature. Differences in the magnitude and timing of these …
New preprint by @alex_winnett @S_Tabachnikova et al.! We asked: which cellular immune signals control viral replication in the nose during the first days of SARS-CoV-2 infection — and how do they change with vaccination? With @ismagilovlab (1/)
medrxiv.org/content/10.64898…
2
30
89
8,898
New preprint by @alex_winnett @S_Tabachnikova et al.! We asked: which cellular immune signals control viral replication in the nose during the first days of SARS-CoV-2 infection — and how do they change with vaccination? With @ismagilovlab (1/)
medrxiv.org/content/10.64898…
6
149
360
49,365
How does vaccination help beyond antibodies? Vaccinated individuals had higher tissue-resident memory T cell (TRM) signatures in the nasal mucosa and mounted Type II IFN responses earlier. This points to mucosal TRM as a key mechanism — and a target for next-gen vaccines. (5/)
4
12
77
3,839
